Novo Nordisk also says it work closely with the FDA to monitor the safety of its medicines
You may be a good candidate if: Youre an adult with a body mass index (BMI) of 30 or higher
Others are newly active adults who have discovered that enthusiasm often recovers faster than the body attached to it
Stacking overview Commercial sources sometimes describe 5-Amino-1MQ as 'complementary' to GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for metabolic research interest
This leads to less fat being absorbed and more energy being burned, which may explain part of GLP-1s effectiveness in supporting weight management (Singh et al, 2024)
The closest performing GLP-1 medicine in terms of average weight loss is Novo Nordisks CagriSema, an Amylin/GLP-1 dual agonist, which had an average weight loss of 22.7% after 68 weeks in Phase 3 trials